A randomised trial of maintenance weekly paclitaxel versus observation following remission with first-line induction carboplatin and paclitaxel for patients with ovarian cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN48397858

Enrollment

1200

Registered

2002-10-15

Start date

2002-12-16

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ovarian cancer Cancer Malignant neoplasm of ovary

Interventions

Maintenance chemotherapy: paclitaxel 70 mg/m^2 weekly, beginning three weeks after the last cycle of carboplatin/paclitaxel induction therapy and continuing for 15 weeks. Updated 11/10/2012: please n

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1. Histologically confirmed epithelial ovarian cancer, fallopian tube cancer and primary peritoneal cancer 2. Female, aged 18 years and over 3. International Federation of Gynecology and Obstetrics (FIGO) stage III to IV. Receive six cycles of carboplatin/paclitaxel, three-weekly at registration 4. Able to complete quality of life questionnaires 5. Can comply with follow-up requirements. Written informed consent 6. Response to induction treatment (as demonstrated by a Computed Tomography [CT] scan)

Exclusion criteria

Exclusion criteria: 1. Patients with peritoneal carcinomatosis of 'uncertain' origin which is mucin-secreting 2. Histological evidence of an origin in the gastrointestinal tract, bilary system or lung

Design outcomes

Secondary

Measure	Time frame
Not provided at time of registration	—

Primary

Measure	Time frame
Progression-free survival	—

Countries

Australia, United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026